|Bid||66.16 x 1400|
|Ask||66.99 x 1200|
|Day's range||65.89 - 67.15|
|52-week range||56.56 - 78.94|
|Beta (5Y monthly)||0.40|
|PE ratio (TTM)||277.54|
|Earnings date||28 Jul 2021 - 02 Aug 2021|
|Forward dividend & yield||2.84 (4.26%)|
|Ex-dividend date||14 Jun 2021|
|1y target est||74.49|
Gilead's (GILD) wholly owned subsidiary Kite signs partnership deal with Shoreline Biosciences to develop novel cell therapies for cancer.
In the latest trading session, Gilead Sciences (GILD) closed at $67.22, marking a -0.16% move from the previous day.
Andy Slavitt, former White House COVID-19 Response Team adviser, author of ‘PREVENTABLE: The Inside Story of How Leadership Failures, Politics, and Selfishness Doomed the U.S. Coronavirus Response’, joins Yahoo Finance to discuss the COVID-19 response in the U.S. and the Supreme court upholding the Affordable Care Act.